Gilead Wins FDA Accelerated Approval for First Hepatitis Delta Treatment
Event summary
- FDA granted accelerated approval to Gilead’s Hepcludex (bulevirtide-gmod) for chronic hepatitis delta virus (HDV) on May 22, 2026.
- Approval based on Phase 3 MYR301 study showing reductions in HDV RNA and ALT normalization at Week 48.
- Hepcludex is the first and only FDA-approved treatment for HDV in the U.S., addressing a disease affecting ~40,000-80,000 Americans.
- Continued approval contingent on confirmatory trial verifying clinical benefit.
- Hepcludex is a once-daily injectable therapy blocking HDV and HBV entry into liver cells.
The big picture
Gilead’s approval marks a significant milestone in addressing chronic HDV, a severe form of viral hepatitis with rapid disease progression and high mortality rates. The FDA’s accelerated pathway reflects the urgent unmet need, but Gilead must now prove long-term efficacy to maintain market access. This approval strengthens Gilead’s position in liver disease therapeutics, complementing its existing portfolio in HBV and HCV treatments.
What we're watching
- Clinical Validation
- Whether confirmatory trials will demonstrate long-term clinical benefits to secure permanent approval.
- Market Penetration
- The pace at which Hepcludex adoption will grow among the estimated 40,000-80,000 HDV patients in the U.S.
- Competitive Landscape
- How Gilead will defend its first-mover advantage as other HDV treatments potentially enter development.
Related topics